Cap Innov'Est 2

RDS is a healthcare technology startup focused on remote patient monitoring solutions, with its flagship product, MultiSense®. This innovative platform enables healthcare professionals to continuously track patients' physiological parameters both in hospitals and at home, promoting enhanced patient pathways and care efficiencies. MultiSense® combines a wearable monitor that captures high-accuracy data with a cloud platform that transforms this information into actionable clinical insights. Aimed primarily at hospitals and healthcare institutions, the solution facilitates early hospital discharge and helps reduce hospital stays, thereby contributing to significant healthcare savings. MultiSense® has received CE marking and is available for sale in several European countries, generating recurring revenues through a fee-for-service model. The product has garnered multiple awards and support from a community of clinicians, while RDS also offers training and support to help healthcare systems effectively utilize the technology. The company is driven by a team of experienced professionals with extensive backgrounds in technology, healthcare, and biotech.

VistaCare is a French company specializing in the development, manufacturing, and distribution of medical devices designed for the treatment of acute and chronic wounds. The company focuses on innovative, non-contact treatment methods that operate in a controlled environment. Their technology addresses critical aspects of wound care, including the reduction of nosocomial risks, visual monitoring of wound progression, and tailored medical protocols based on the specific type and stage of each wound. By enhancing the quality of life for patients and streamlining the care process for caregivers, VistaCare aims to significantly reduce treatment times and hospital stays, offering a more effective solution for complex wounds that are challenging to manage with conventional therapies.

Opencell, founded in 2015, offers an open source monetization and billing platform designed to address the complexities of billing in various sectors, including telecommunications, cloud services, IoT, and utilities. The platform emerged from a telco billing project initiated in 2007 by CEO David Meyer. It aims to bridge the gap between expensive legacy billing systems and simplistic SaaS solutions that often fail to meet diverse customer needs. With over 40 successful implementations across multiple industries and countries, Opencell provides an integrated revenue management platform that enables businesses to effectively administer subscriptions and usage-based revenues, simplifying complex billing processes for a wide range of clients.

Defymed is a leader in the development of innovative implantable medical devices aimed at transforming therapeutic administration. The company focuses on minimizing adverse events associated with traditional treatment methods through precise, site-specific drug delivery. Its pioneering technologies include MailPan®, a physiologic cell encapsulation device, and ExOlin®, a targeted drug delivery device currently in clinical trials. These devices are designed to address various therapeutic needs, such as type 1 diabetes, hemophilia, and cancer management, thus improving clinical outcomes and patient comfort. Defymed's proprietary technology and expertise position it as a versatile platform for multiple applications in the medical field. The company is certified under ISO13485:2016 and boasts a strong global network of experts in cell therapy and drug delivery. Defymed has received numerous accolades in Europe and the USA for its innovative approaches to enhancing patients' treatment experiences.

Syndivia is a biotechnology company focused on developing innovative cancer therapeutics aimed at treating patients with challenging cancer indications. The company leverages the unique properties of tumor hallmarks and the tumor microenvironment to create targeted antibody-drug conjugates (ADCs) that feature optimal drug-to-antibody ratios. By doing so, Syndivia aims to enhance antitumor efficacy and improve safety for cancer patients, ultimately striving to deliver the most effective treatments available.

Urania Therapeutics is a biopharmaceutical company focused on developing innovative therapies for genetic diseases and cancers caused by mutations. The company specializes in the identification and creation of readthrough compounds that address premature stop codons during protein synthesis. By facilitating the production of full-length proteins, these compounds aim to treat a variety of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its unique structure-based drug design platform, Urania Therapeutics seeks to restore the production of functional proteins, thereby offering new therapeutic options for patients with these challenging conditions.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Medsenic SAS is a privately held pharmaceutical company based in Paris, France, specializing in the development of drugs for the treatment of autoimmune diseases, including systemic lupus erythematosus and graft-versus-host diseases. Founded in 2010, the company also produces arsenic trioxide, which is utilized in the treatment of acute promyelocytic leukemia, demonstrating significant potential for achieving remarkable remissions and addressing severe health conditions.

Opencell, founded in 2015, offers an open source monetization and billing platform designed to address the complexities of billing in various sectors, including telecommunications, cloud services, IoT, and utilities. The platform emerged from a telco billing project initiated in 2007 by CEO David Meyer. It aims to bridge the gap between expensive legacy billing systems and simplistic SaaS solutions that often fail to meet diverse customer needs. With over 40 successful implementations across multiple industries and countries, Opencell provides an integrated revenue management platform that enables businesses to effectively administer subscriptions and usage-based revenues, simplifying complex billing processes for a wide range of clients.

Inoviem Scientific SAS is a contract research biotechnology company based in Strasbourg, France, founded in 2011. The company specializes in developing advanced technologies for analyzing drug-target interactions under physiological conditions using human tissues. Its proprietary technologies include physiological intermolecular modulation spectroscopy, which examines the interactions of exogenous molecules with tissue, and techniques for isolating protein complexes and reconstructing their three-dimensional structures. Inoviem Scientific offers a range of services across the drug development spectrum, including target identification, lead optimization, preclinical and clinical development, and biomarker testing. The company serves a diverse clientele, including private and academic laboratories, as well as the pharmaceutical and biotechnology industries. By leveraging its innovative technologies, Inoviem Scientific aims to enhance the drug development process, improve the selection of lead compounds, and reduce attrition rates, ultimately accelerating the delivery of new therapeutic solutions.

PeptiMimesis specializes in the design, discovery, and early development of transmembrane therapeutic peptides. The company's innovative approach focuses on identifying peptidomimetic candidates that can interfere with the hetero- and homodimerization of target receptors. PeptiMimesis is developing a pipeline aimed at key targets in oncology, immuno-oncology, and immune diseases. Additionally, the company is open to collaborating with pharmaceutical partners on specific receptors of interest, thereby enhancing the potential for therapeutic advancements in these critical areas of healthcare.

FiberMetrix specializes in innovative solutions for real-time radiation dose monitoring in both medical and industrial sectors. The company utilizes patented optical fiber technology to develop sensors that provide automatic feedback on radiation exposure, enhancing radiation awareness for patients and professionals alike. With expertise in radiation detection and dosimetry, FiberMetrix creates both fully integrated and handheld sensors with variable geometry, allowing for precise and flexible measurement capabilities. These systems enable rapid and efficient monitoring of radiation doses, ensuring safety and compliance in all radiation-related applications.

WizzVet is an interactive platform designed for veterinary telemedicine, functioning as a professional social network. It promotes continuous training and facilitates the exchange of knowledge within the veterinary community. The platform offers a wide range of web conferences, featuring two to three new online courses each week that provide continuing education points. Additionally, WizzVet enables veterinarians to post queries and communicate using various elements such as photos, sampling results, and medical imaging, allowing isolated practitioners to seek assistance from online expert networks for complex cases requiring technical advice or medical collaboration.

PeptiMimesis specializes in the design, discovery, and early development of transmembrane therapeutic peptides. The company's innovative approach focuses on identifying peptidomimetic candidates that can interfere with the hetero- and homodimerization of target receptors. PeptiMimesis is developing a pipeline aimed at key targets in oncology, immuno-oncology, and immune diseases. Additionally, the company is open to collaborating with pharmaceutical partners on specific receptors of interest, thereby enhancing the potential for therapeutic advancements in these critical areas of healthcare.

Opencell, founded in 2015, offers an open source monetization and billing platform designed to address the complexities of billing in various sectors, including telecommunications, cloud services, IoT, and utilities. The platform emerged from a telco billing project initiated in 2007 by CEO David Meyer. It aims to bridge the gap between expensive legacy billing systems and simplistic SaaS solutions that often fail to meet diverse customer needs. With over 40 successful implementations across multiple industries and countries, Opencell provides an integrated revenue management platform that enables businesses to effectively administer subscriptions and usage-based revenues, simplifying complex billing processes for a wide range of clients.

Defymed is a leader in the development of innovative implantable medical devices aimed at transforming therapeutic administration. The company focuses on minimizing adverse events associated with traditional treatment methods through precise, site-specific drug delivery. Its pioneering technologies include MailPan®, a physiologic cell encapsulation device, and ExOlin®, a targeted drug delivery device currently in clinical trials. These devices are designed to address various therapeutic needs, such as type 1 diabetes, hemophilia, and cancer management, thus improving clinical outcomes and patient comfort. Defymed's proprietary technology and expertise position it as a versatile platform for multiple applications in the medical field. The company is certified under ISO13485:2016 and boasts a strong global network of experts in cell therapy and drug delivery. Defymed has received numerous accolades in Europe and the USA for its innovative approaches to enhancing patients' treatment experiences.

Inoviem Scientific SAS is a contract research biotechnology company based in Strasbourg, France, founded in 2011. The company specializes in developing advanced technologies for analyzing drug-target interactions under physiological conditions using human tissues. Its proprietary technologies include physiological intermolecular modulation spectroscopy, which examines the interactions of exogenous molecules with tissue, and techniques for isolating protein complexes and reconstructing their three-dimensional structures. Inoviem Scientific offers a range of services across the drug development spectrum, including target identification, lead optimization, preclinical and clinical development, and biomarker testing. The company serves a diverse clientele, including private and academic laboratories, as well as the pharmaceutical and biotechnology industries. By leveraging its innovative technologies, Inoviem Scientific aims to enhance the drug development process, improve the selection of lead compounds, and reduce attrition rates, ultimately accelerating the delivery of new therapeutic solutions.

Bionext S.A. is a biotechnology company based in Strasbourg, France, founded in 2009. It specializes in bioinformatics and the development of three-dimensional molecular visualization software tailored for the pharmaceuticals and biotechnology sectors. The company focuses on integrating big data, cloud computing, and OMICS data to enhance drug discovery processes. Bionext's platform enables visualization and simulation of drug interactions within human cells, facilitating a deeper understanding of drug behavior and aiding in drug repurposing and profile assessment. Additionally, the Bionext Virtual Screening platform models the cellular environment to support high-throughput screening, allowing for early assessment of molecular functions, side effects, and efficacy throughout the development stages of new compounds across various industries, including pharmacy, cosmetics, and agri-food.